Vaccines for metastatic hormone-refractory prostate cancer

Canadian Coordinating Office for Health Technology Assessment
Record ID 32006000027
English, French
Authors' objectives:

The aim of this study was to summarize the available information on the use of Sipuleucel-T [Provenge (formerly APC8015)] and granulocyte macrophage-colony stimulating factor (GM-CSF) gene-transduced tumour vaccine (GVAX) as therapeutic vaccines in men with metastatic hormone-refractory prostate cancer (HRPC).

Authors' recommendations: There are no therapeutic vaccines approved for use for prostate cancer in Canada or the US. To be effective, a therapeutic vaccine must demonstrate the ability to elicit an appropriate tumour-specific response, and have a favourable safety profile. Provenge is safe and well-tolerated. It targets a specific protein for prostate cancer and demonstrates a statistically significant survival benefit. Further clinical trials should compare Provenge with the current treatment standard (Taxotere plus prednisone), as is being done in the GVAX clinical trials. GVAX is safe and well-tolerated. Because it is not patient specific, it will be available on an outpatient basis to any patient. If GVAX makes it to the market, it could prove to be a convenient addition to the limited treatment arsenal that is available for men with metastatic HRPC.
Authors' methods: Overview
Project Status: Completed
URL for project:
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Cancer Vaccines
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Prostatic Neoplasms
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.